Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphangioleiomyomatosis

M Kitaichi1, T Izumi

  • 1Chest Disease Research Institute, Kyoto University, Japan.

Current Opinion in Pulmonary Medicine
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Pulmonary lymphangioleiomyomatosis (PLAM) is a rare lung disease in women of reproductive age. Diagnosis involves lung biopsy, and while hormonal therapy may help with fluid buildup, lung changes can persist or worsen.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymphatic manifestations of lymphangioleiomyomatosis.

Lymphology·2014
Same author

Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serum IL-7 as a prognostic marker.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2011
Same author

Risk factors of acute exacerbation of idiopathic pulmonary fibrosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2011
Same author

Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease.

European respiratory review : an official journal of the European Respiratory Society·2010
Same author

Long-term complications and prognosis of chronic beryllium disease.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2009
Same author

Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia.

The European respiratory journal·2008
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Area of Science:

  • Pulmonology
  • Oncology
  • Pathology

Background:

  • Pulmonary lymphangioleiomyomatosis (PLAM) is a rare, chronic lung disease affecting women of childbearing age.
  • Its etiology is unknown, and it is characterized by the proliferation of atypical smooth muscle cells in the lungs.
  • Clinical presentation includes airflow limitation, pulmonary infiltrates, and lung cysts.

Purpose of the Study:

  • To summarize the clinical features, diagnosis, treatment effects, and prognostic factors of pulmonary lymphangioleiomyomatosis.
  • To highlight recent diagnostic advancements and therapeutic outcomes.

Main Methods:

  • Review of clinical features, diagnostic methods (open lung biopsy, transbronchial biopsy), and treatment responses.
  • Analysis of prognostic factors based on pulmonary function tests and histological findings.

Related Experiment Videos

Main Results:

  • Diagnosis can be confirmed via transbronchial biopsy, not just open lung biopsy.
  • Hormonal manipulation therapy shows benefits for chylothorax/chylous ascites.
  • Pulmonary parenchymal changes may remain stable or progress despite therapy.

Conclusions:

  • PLAM is a debilitating disorder with varied clinical presentations and diagnostic approaches.
  • While hormonal therapy can manage effusions, its effect on lung parenchymal disease requires further investigation.
  • Pulmonary function and histology are key prognostic indicators.